Coronavirus Vaccine Candidates
Coronaviruses without preventive vaccines are the Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV), and the novel coronavirus SARS-CoV-2, which was initially detected in Wuhan, China by the WHO, during December 2019.
To date, more than 1,000 studies addressing various aspects of COVID-19 are registered on ClinicalTrials.gov, including more than 600 interventional studies and randomized clinical trials (RCTs). Preliminary results from some RCTs have already been reported in social media and the press.
There are various approaches and different technologies developing vaccine candidates against the SARS-CoV-2 coronavirus. These approaches include, but are not limited to, Viral vector vaccine, DNA vaccine, RNA vaccine, Live-attenuated vaccine, and Protein-based vaccine.
SARS-CoV-2 Coronavirus Vaccine Candidates Conducting Human Clinical Trials
Phase 4 - Bacille Calmette-Guerin (BCG)
Phase 3 - VPM1002 Tuberculosis (BCG) Vaccine
Phase 2 - mRNA-1273 SARS-CoV-2 Vaccine
Phase 2 - AZD1222 SARS-CoV-2 vaccine
Phase 1 - Adenovirus Type 5 Vector vaccine candidate (“Ad5-nCoV”)
Phase 1 - INO-4800 DNA Coronavirus Vaccine
Phase 1 - Johnson & Johnson has identified a lead COVID-19 vaccine candidate
Phase 1 - NVX-CoV2373 SARS-CoV-2 Vaccine
Phase 1 (pending) Sanofi - GSK SARS-CoV-2 Vaccine
Phase 1 (pending) Vaxart COVID-19 Oral Vaccine
Coronavirus Clinical Trial Overview
The need to rapidly develop a vaccine against SARS-CoV-2 comes at a time of the explosion in basic scientific understanding, including in areas such as genomics and structural biology, that is supporting a new era in vaccine development, commented an article in NEJM on May 21, 2020.
Among those with the greatest potential for speed are DNA- and RNA-based platforms, followed by those for developing recombinant-subunit vaccines. RNA and DNA vaccines can be made quickly because they require no culture or fermentation, instead of using synthetic processes.
How will interested persons, clinicians, and politicians understand the results of these much-anticipated and critically needed clinical trials? This editorial published in JAMA on May 4, 2020, presents a clear overview.
COVID-19 disease pandemic news is available at CoronavirusToday.com
Content sources on this webpage include, but are not limited to, the WHO, the CDC, industry studies, and clinicalTrials.gov. The content was Fact-Checked by Dr. Robert Carlson and other healthcare professionals.